Assistant Professor, Medicine, UCLA School of Medicine

Hematology

Dr. Zev A. Wainberg, MD

Wainberg practices Hematology. He went to medical school at Albert Einstein College of Medicine. Wainberg is also a published doctor. He has 32 paper published. The most recent paper is: Modulation of stress protein (hsp27 and hsp70) expression in CD4+ lymphocytic cells following acute infection with human immunodeficiency virus type-1. He is registered with Medicare.

Publications

Prognostic Effect of Ultra-Staging Node-Negative Colon Cancer Without Adjuvant Chemotherapy: A Prospective National Cancer Institute-Sponsored Clinical Trial.
Immunoprofiling for Prognostic Assessment of Colon Cancer: a Novel Complement to Ultrastaging.
A Single Institution Experience in Compliance with Universal Screening for Lynch Syndrome in Colorectal Cancer.
Value of Primary Tumor Gene Signatures in Colon Cancer When National Quality Standards are Adhered to: Preliminary Results of an International Prospective Multicenter ...
Physical function and quality of life in frail and/or elderly patients with metastatic colorectal Cancer treated with capecitabine and bevacizumab: an exploratory anal...
Bilateral Subfoveal Neurosensory Retinal Detachment Associated With MEK Inhibitor Use for Metastatic Cancer.
Erratum to: Phase I study of PF-04691502, a small-molecule, oral, dual inhibitor of PI3K and mTOR, in patients with advanced Cancer.
A phase 1, open-label, dose-escalation study of BIIB022 (anti-IGF-1R monoclonal antibody) in subjects with relapsed or refractory solid tumors.
Phase I study of PF-04691502, a small-molecule, oral, dual inhibitor of PI3K and mTOR, in patients with advanced Cancer.
A phase II trial of frontline capecitabine and bevacizumab in poor performance status and/or elderly patients with metastatic colorectal Cancer.
A Phase 1B Study of Dulanermin in Combination With Modified FOLFOX6 Plus Bevacizumab in Patients With Metastatic Colorectal Cancer.
Inhibition of HSP90 with AUY922 Induces Synergy in HER2-Amplified Trastuzumab-Resistant Breast and Gastric Cancer.
Time-Dependent Trends in Lymph Node Yield and Impact on Adjuvant Therapy Decisions in Colon Cancer Surgery: An International Multi-Institutional Study.
Adjuvant treatment of early colon Cancer with micrometastases: Results of a national survey.
Transarterial chemoembolization plus or minus intravenous bevacizumab in the treatment of hepatocellular Cancer: A pilot study.
Targeted therapies for metastatic esophagogastric Cancer.
Monoclonal antibody targeting of N-cadherin inhibits prostate Cancer growth, metastasis and castration resistance.
Phospho-Akt pathway activation and inhibition depends on N-cadherin or phospho-EGFR expression in invasive human bladder Cancer cell lines.
Lapatinib, a dual EGFR and HER2 kinase inhibitor, selectively inhibits HER2-amplified human gastric Cancer cells and is synergistic with trastuzumab in vitro and in vivo.
Adjuvant Chemotherapy for Stage II Colon Cancer: The Role of Molecular Markers in Choosing Therapy.
Heat shock proteins: novel therapeutic tools for HIV-infection?
Modulation of stress protein (hsp27 and hsp70) expression in CD4+ lymphocytic cells following Acute infection with human immunodeficiency virus type-1.
Surgical quality and nodal ultrastaging is associated with long-term disease-free survival in early colorectal Cancer: an analysis of 2 international multicenter prosp...
Impact of tumor grade on prognosis in pancreatic Cancer: should we include grade in AJCC staging?
Panitumumab in colon Cancer: a review and summary of ongoing trials.
A phase III randomized, open-label, controlled trial of chemotherapy and bevacizumab with or without panitumumab in the first-line treatment of patients with metastati...
Targeted lymph node evaluation in colorectal Cancer: a decade of progress!
Panitumumab in colorectal Cancer.
Acute lymphoblastic leukemia presenting as Acute renal failure.
Phase II trial of modified FOLFOX6 and erlotinib in patients with metastatic or advanced adenoCarcinoma of the oesophagus and gastro-oesophageal junction.
Lapatinib in Combination With Capecitabine Plus Oxaliplatin in Human Epidermal Growth Factor Receptor 2-Positive Advanced or Metastatic Gastric, Esophageal, or Gastroe...

Schools

Tel Aviv University Sackler Faculty of Medicine
Montefiore Med Center
UCLA Med Center

Procedures Preformed

Cardiac MRI (Magnetic Resonance Imaging) of Heart or Chest
Thoracentesis

Conditions Treated

Acute Leukemia
Adrenal Gland Cancer
Anal and Rectal Cancer
Anemia
View All

Doctors Specialties

Hematology
Medical Oncology
Oncology

Accepted Insurances

Education

UCLA Medical Center
Albert Einstein College of Medicine
Tel Aviv University Sackler

Hospital

Ronald Reagan UCLA Medical Center
Santa Monica-UCLA Medical Center and Orthopaedic Hospital

Drug Facts

NPI NUMBER		1104850932
NPPES Provider LastName		WAINBERG
NPPES Provider FirstName		ZEV
NPPES Provider ZIPCode		900950001
NPPES Provider State		CA
Specialty Description		General Surgery
Total Claim Count		223.0
Distinct Opioid Count		0.0
Opioid Claim Count		0.0
Percent Opioid Claims		0.0

Helpful Reviews

Give Anonymous Review

Medicare Facts

National Provider Identifier [NPI]	1104850932
Last Name Of The Provider	WAINBERG
First Name Of The Provider	ZEV
View All

Similar Doctors

	Dr. Jeffrey Eckardt, MD This Doctor is OpenDoctor Recommended.
	Dr. Lauren C. Pinter-Brown, MD This Doctor is OpenDoctor Recommended.
	Dr. Herbert A. Eradat, MD This Doctor is OpenDoctor Recommended.
	Dr. Sean A. Fischer, MD This Doctor is OpenDoctor Recommended.
	Dr. Sebastian J. Sasu, MD This Doctor is OpenDoctor Recommended.
	Dr. Susan Bukata, MD This Doctor is OpenDoctor Recommended.
	Dr. Kathryn A. Henick, MD
	Dr. Saeed W. Sadeghi, MD This Doctor is OpenDoctor Recommended.
	Dr. Doris V. Quon, MD This Doctor is OpenDoctor Recommended.
	Dr. Sven Devos, MD This Doctor is OpenDoctor Recommended.
	Dr. Lee S. Rosen, MD This Doctor is OpenDoctor Recommended. This doctor has more publications